Board of Directors

Dave Van Meter
President & Chief Executive Officer

Dave joined lvantis as President and CEO in January 2008. Prior to joining lvantis, Dave held various positions of increasing responsibility in Marketing and General Management throughout his career, most recently at Abbott Vascular, where he began in August 2001. Dave was an early leader in the creation and growth of Abbott’s Vascular division, a business that grew from $60 to $400 MM from 2001 until 2006. At Abbott, Dave held several positions, including Director of US Marketing, and, ultimately, Vice President and General Manager, Coronary Technologies. In July 2006, following the Abbott acquisition of Guidant’s Vascular Intervention (VI) business, Dave became Vice President, Strategic Marketing, Cardiac Therapies for the new Abbott Vascular, and, in 2007, became Vice President, Strategic Marketing, tor all of Abbott Vascular, a nearly $2 billion business at the time, which was the role he held prior to joining lvantis. Prior to joining Abbott Vascular, Dave worked in various levels of management for other notable companies, including Applied Medical and US Surgical (acquired by Tyco Healthcare). Dave is a graduate of Hillsdale College (Hillsdale, Ml) with a double major in English and Political Science, and received his MBA from the University of Notre Dame.

Randy Alexander
Independent Board Member

Randy is a seasoned senior medical device executive and leader in the ophthalmic industry. Mr. Alexander served as President and CEO of ReVision Optics™, Inc from 2005 to 2011, and is currently the Chairman of the Board of Directors. Prior to that time Mr. Alexander was President and CEO of IntraLase Inc., growing the business from a start-up to over $18 million in revenue in a little over four years. During this period, Mr. Alexander was instrumental in raising $75 million in capital for IntraLase. The company was eventually acquired by Advanced Medical Optics (AMO). Prior to IntraLase, Mr. Alexander was Senior Vice President of Chiron Vision, where he established Chiron Vision as a leader in the refractive surgery industry. At Chiron Vision, he created a $50 million refractive product line by identifying the LASIK surgical procedure, acquiring patents, and instrumentation. During his 28-year career in ophthalmology, Mr. Alexander has also served as CEO of Pharmacia Intermedics and Senior Vice President, Sales & Marketing of CILCO. Mr. Alexander holds BS and MS degrees in Biological Sciences from Marshall University.

Ali Behbahani, MD
New Enterprise Associates, Special Partner

Ali joined NEA in 2007 and is a Partner on the healthcare team. He specializes in investments in the biopharmaceutical, medical device, specialty pharmaceutical, and healthcare services sectors. Prior to joining NEA, Ali worked as an intern and later as a consultant in business development at The Medicines Company, a specialty pharmaceutical company developing acute care cardiovascular products. He previously held positions as a Venture Associate at Morgan Stanley Venture Partners and as a Healthcare Investment Banking Analyst at Lehman Brothers. He conducted basic science research in the fields of viral fusion inhibition and structural proteomics at the National Institutes of Health and at Duke University. Ali concurrently earned his MD degree from The University of Pennsylvania School of Medicine and his MBA degree from The University of Pennsylvania Wharton School, where he graduated with Honors and was a Palmer Scholar. He graduated summa cum laude and received his bachelor’s degrees with distinction in Biomedical Engineering, Electrical Engineering, and Chemistry from Duke University.

Tara Butler, MD
Ascension Health Ventures

Tara joined AHV in 2002 after completing a residency in obstetrics and gynecology at Washington University in St. Louis. She primarily focuses on investments in the medical device and diagnostics sector. Tara has been a board member or observer at several AHV portfolio companies, including Augmenix, CHF Solutions, Confluent Surgical, HemoSphere, Interventional Spine, ISTO Technologies, MindFrame, Neurolutions, Novasys, Ocular Therapeutix, OptiScan Biomedical, PathoGenetix, Stereotaxis (NASD:STXS), and TomoTherapy (NASD:TOMO). Prior to attending medical school, she held positions in business development at Medtronic, in finance at Honeywell and as a laboratory research assistant at the University of Pennsylvania School of Medicine. She holds a BS in Economics and an MBA from the Wharton School of Business at the University of Pennsylvania, and a Doctor of Medicine from the University of Pennsylvania School of Medicine.

Ben Gust
GBS Venture Partners

Ben Gust BSc, LLB, GDipAppFin, GAICD joined GBS in 2003 following several years in the legal industry practicing as a Solicitor and managing international litigation. Ben is admitted to the Victorian Supreme Court as a Barrister and Solicitor, earned his Bachelor of Law and Bachelor of Science degrees from Monash University in Melbourne and has a GDip. in Applied Finance and Investment. Ben has held board positions on a number of portfolio companies including acting as the company secretary for an ASX listed entity and is currently on the board Hydrexia Pty Ltd, Hatchtech Pty Ltd, Spinifex Pty Ltd, Mimetica Ltd, Ivantis Inc, and chair of the audit committee of Neuromonics Pty Ltd.

Doug Roeder
Delphi Ventures, General Partner

Doug joined Delphi Ventures as an Associate in 1998 and became a Partner in 2000. His primary investment focus at Delphi is on medical devices and diagnostics. Prior to joining Delphi, Doug was an Associate with Alex. Brown’s Healthcare Investment Banking Group in San Francisco. While at Alex. Brown, Doug assisted in the execution of over a dozen financing and merger transactions involving both Fortune 500 and venture-backed medical technology companies, including a number of Delphi portfolio companies. Previously, Doug was with Putnam Associates, a consulting firm focused on the biopharmaceutical industry, where his primary role was to develop and implement a strategy for the launch of a leading biotech drug. Doug’s board involvement includes the following: Anulex Technologies, Inc., Evalve, Inc., Labcyte, Inc., Soteira, Inc., TranS1, Inc. (TSON), TriVascular, Inc., and Vibrynt, Inc. Doug holds an AB from Dartmouth College.

Yoh-Chie Lu
Vertex Healthcare, Venture Partner

Mr. Lu has more than 30 years’ experience in the medical industry. He was the founder of Biosensors International Group Ltd, where he was chairman and CEO from its inception until 2008. He retained his leadership position as chairman of the Group from January 2008 until November 2016. Prior to starting Biosensors in 1990, Mr. Lu established Asia-based operations for the Medical Division of Gould Inc in Tokyo in 1978. In 1986, he participated in a management-led leveraged buyout of the division from Gould and he continued as president of the Asia-Pacific division through 1988. Mr. Lu took the company to IPO on the Nasdaq and it was subsequently sold to British Oxygen Corporation. He served as president of Asia-Pacific with British Oxygen until 1990. Mr. Lu is active in both the international and local medical arena as an entrepreneurial angel investor. Yoh-Chie also serves on the board of directors for Earlens, Moximed, Visterra, and Innoventures.

Please Select Your Country